Status: Recruiting
ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection
Single-arm trial to evaluate the safety and efficacy of ACX-362E \[ibezapolstat\] in patients with recurrent C. difficile infection (CDI).
Participants needed: 20
Trial details
Phase: Phase 2Age: 18-90Biological sex: AllType: InterventionalSponsor: Acurx Pharmaceuticals Inc.Updated: Aug 12, 2026Locations: 15
Eligibility criteria
Confirmed diagnosis of CDI as defined by 1) the presence of diarrhea, defined as... [+2]
Severe, complicated, or life-threatening fulminant CDI with evidence of hypotens... [+7]